Skip to content
MarketScale
‹ Back to IndustriesSciences

Filament Winding Enables New Frontiers for Rocketry

Earlier this year, when SpaceX successfully launched their Falcon Heavy rocket, it made headlines across the world. Including the Tesla Roadster, the rocket carried an enormous payload, second only to the Saturn V rocket, and did it with a significant emphasis on composite materials.[1] It’s incredible to realize the precise engineering and design that went…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
Filament Winding Enables New Frontiers for Rocketry

Key takeaways

01

Earlier this year, when SpaceX successfully launched their Falcon Heavy rocket, it made headlines across the world.

02

Including the Tesla Roadster, the rocket carried an enormous payload, second only to the Saturn V rocket, and did it with a significant emphasis on composite materials.[1] It’s incredible to realize the precise engineering and design that went…

Earlier this year, when SpaceX successfully launched their Falcon Heavy rocket, it made headlines across the world. Including the Tesla Roadster, the rocket carried an enormous payload, second only to the Saturn V rocket, and did it with a significant emphasis on composite materials.[1] It’s incredible to realize the precise engineering and design that went into making the mission a success. Seemingly minor flaws in the carbon fiber elements of the rocket, or even improper tools used during construction, could have resulted in catastrophe.

A New Use for a Tried and True Practice

Filament winding is certainly not a new process for manufacturing composite structures, but utilizing a filament winder that gives you complete control is imperative—particularly when construction processes must take into account the extreme conditions and incredible forces rockets need to withstand. When designing and manufacturing a product to meet exact end-goal specifications, you need to trust the tools you’re using.

This is especially true with filament winding. It is a process in which long, continuous strands of composite material are wound around a supporting structure to give it a desired shape. The support, called a mandrel, is then either removed, leaving a hollow but strong and durable structure, or left inside to prevent leakages from whatever may be contained within the structure.[2] While the process is frequently used for everyday objects like street lamps and golf club shafts, the capabilities of carbon fiber composites have broadened the possibilities of filament winding in creating rocket casings and fuselages that meet the exacting needs of aerospace engineers.

Composites Cut Costs for Aerospace Companies 

Take the recent SpaceX success, for example. By forgoing traditional materials and turning to carbon fiber, the Falcon Heavy rocket was able to carry 119 thousand pounds, more than twice that of its closest competitor, for a third of the cost.[3] Composites give companies flexibility in creating materials that are specific to their project. With the variety of missile systems out there, this flexibility is crucial—the composites necessary for a launch into space are vastly different than those needed for defensive missiles or even long-range deterrent systems.[4] As carbon fiber costs drop, accessibility to more companies rises, allowing for the construction of composite designs that can fit a wide range of engineering needs. But employing the right tools to utilize those composites is vital.

MVP Leads the Way for Filament Winding 

When seeking out a filament winder to manufacture their parts, time and time again, companies turn to Magnum Venus Products (MVP). With more than four decades of experience designing and producing turnkey winding solutions, MVP is the industry leader when it comes to high production filament winding machines. Not only do they allow for customizations like dual side production and fully integrated pumping systems, but MVP’s filament winders can be manufactured to the specific level of control and number of axes needed for each unique project.

A top manufacturer of composite application equipment, MVP has provided solutions to meet the most demanding requirements and challenging of environments for a wide array of industries. Not only can they provide a filament winding system that fits the exact specifications needed for rocketry, but they offer a full line of superior equipment, including prep machines, extractors, mandrels and more. To learn more about MVP’s state-of-the-art, customizable filament winders, or to see their huge inventory of cutting-edge products, visit mvpind.com today!

[1] http://compositesmanufacturingmagazine.com/2018/02/spacex-falcon-heavy-carbon-fiber-composites/

[2] https://www.sciencedirect.com/science/article/pii/025405849501554X

[3] http://compositesmanufacturingmagazine.com/2018/02/spacex-falcon-heavy-carbon-fiber-composites/

[4] https://www.compositesworld.com/articles/composites-target-tactical-missiles

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512